SMi is thrilled to present the return of its 4th annual immunogenicity conference, taking place in London, 12th - 13th June 2017.

This conference will provide guests with a thorough understanding of the continued research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins. Delegates will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and insights on how to prosecute state-of-the-art assessment of the clinical immunogenicity of therapeutic proteins.

Considerable progression has been made in immunogenicity over recent years, with innovative developments seen in predicting and controlling immunogenicity. Complex challenges to industry remain however.

At SMi’s 4th annual Immunogenicity conference, industry, regulatory and academic experts will gather to spark debate and progress on the causes of immunogenicity, predicting and preventing its effects, and its associated issues. Immunogenicity 2017 will offer unparalleled networking opportunities, deep insight into industry issues, and spotlight sessions on innovations and emerging technologies for immunogenicity.

Immunogenicity 2017 will explore the need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. We will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for our delegates, Immunogenicity 2017 will highlight and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.


4th annual Immunogenicity Conference

12th – 13th June 2017

London, UK

Contact e-mail: kwilliams@smi-online.co.uk

Contact tel: 44 (0) 207 827 6012

www.immuno.co.uk/globaleventlistings

Related Events

Comments